Introduction
============

Support vector machine is one of the most popular machine learning methods in biomedical sciences with constantly growing impact and more than 11,000 citations in the PubMed-indexed literature^[1](#fn01){ref-type="fn"}^, of those ∼2,300 are only for the 2017 and first 6 months of 2018. This method has been successfully applied for a wide variety of biomedical applications like searching Dicer RNase cleavage sites on pre-miRNA ([@B3]), prediction of miRNA guide strands ([@B1]), identification of poly(A) signals in genomic DNA ([@B2]), finding conformational B-cell epitopes in antigens by nucleotide sequence ([@B6]). More recent developments include drug design according to physicochemical properties ([@B47]), learning on transcriptomic profiles for age recognition ([@B31]), predictions of drug toxicities and other side effects ([@B48]).

The performance quality of the classifiers based on these methods may reach the value of 0.80 or higher for the metrics such as ROC AUC^[2](#fn02){ref-type="fn"}^ and/or accuracy rate, e.g., for problems of age recognition ([@B31]) and drug compound selection ([@B47]). However, although generally clearly helpful, the SVM approach frequently demonstrates insufficient performance in several applications for separating groups of the patients with different clinical outcomes ([@B32]; [@B34]; [@B8]; [@B25]). These failures were most likely caused by insufficient number of preceding clinical cases, which provokes overtraining of all machine learning algorithms. Particularly, the rareness of training points in the feature space leads to frequent extrapolations, and SVM method is known to be highly vulnerable to such conditions ([@B7]; [@B9]; [@B10]; [@B12]).

In order to increase the performance of SVM for distinguishing between clinically relevant features, such as degrees of response to cancer therapies, we propose here a new method termed *FloWPS* for data trimming that generalizes the SVM technique by precluding extrapolation in the feature space. FloWPS acts by selecting for further analysis only those features that lay within the intervals of data projections from the training dataset. This approach can avoid extrapolations in favor of interpolations and thus increases a prediction quality of the output data. FloWPS combines somehow two methods, SVM and kNN ([@B4]), where kNN plays a particular role to extract informative features. The idea to combine feature extraction methods with SVM is well known ([@B38]; [@B26]; [@B39]; [@B29]; [@B40]). The approach proposed in this paper, however, is in principle a novelty, at least because its selection capacity is focused on every single point available for prediction.

We tested FloWPS on ten published gene expression datasets for totally 992 cancer patients treated with different types of chemotherapy with known clinical outcomes. In all the cases, the classifiers built using FloWPS outperformed standard SVM classifiers.

Results
=======

Data Sources and Feature Selection
----------------------------------

In this study, we investigated gene expression features associated with the responses to chemotherapy. The gene expression profiles were extracted from the datasets summarized in Table [1](#T1){ref-type="table"}. The clinical outcome information was related to response on different chemotherapy regimens, linked with high throughput gene expression profiles for the individual patients.

###### 

Clinically annotated gene expression datasets.

  Reference        Dataset ID   Disease type                                            Treatment type                                                                      Experimental platform                Number of samples                          Number of *core marker genes*
  ---------------- ------------ ------------------------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------ ------------------------------------------ -------------------------------
  [@B20]; [@B23]   GSE25066     Breast cancer with different hormonal and HER2 status   Neoadjuvant taxane + anthracycline                                                  Affymetrix Human Genome U133 Array   235 (118 responders, 117 non-responders)   20
  [@B21]           GSE41998     Breast cancer with different hormonal and HER2 status   Neoadjuvant doxorubicin + cyclophosphamide, followed by paclitaxel                  Affymetrix Human Genome U133 Array   68 (34 responders, 34 non-responders)      11
  [@B32]           GSE9782      Multiple myeloma                                        Bortezomib                                                                          Affymetrix Human Genome U133 Array   169 (85 responders, 84 non-responders)     18
  [@B16]           GSE39754     Multiple myeloma                                        Vincristine + adriamycin + dexamethasone followed by ASCT                           Affymetrix Human Exon 1.0 ST Array   124 (62 responders, 62 non-responders)     16
  [@B41]           GSE68871     Multiple myeloma                                        Bortezomib-thalidomide-dexamethasone (VTD)                                          Affymetrix Human Genome U133 Plus    98 (49 responders, 49 non-responders)      12
  [@B5]            GSE55145     Multiple myeloma                                        Bortezomib followed by ASCT                                                         Affymetrix Human Exon 1.0 ST Array   56 (28 responders, 28 non-responders)      14
  [@B19]; [@B45]   TARGET-50    Childhood kidney Wilms tumor                            Vincristine sulfate + non-target drugs + conventional surgery + radiation therapy   Illumina HiSeq 2000                  72 (36 responders, 36 non-responders)      14
  [@B19]; [@B42]   TARGET-10    Childhood B acute lymphoblastic leukemia                Vincristine sulfate + non-target drugs                                              Illumina HiSeq 2000                  60 (30 responders, 30 non-responders)      14
  [@B19]           TARGET-20    Childhood acute myeloid leukemia                        Non-target drugs including busulfan and cyclophosphamide                            Illumina HiSeq 2000                  46 (23 responders, 23 non-responders)      10
  [@B19]           TARGET-20    Childhood acute myeloid leukemia                        Non-target drugs excluding busulfan and cyclophosphamide                            Illumina HiSeq 2000                  124 (62 responders, 62 non-responders)     16
                                                                                                                                                                                                                                                            

Each patient was primarily labeled as either responder or non-responder to a treatment. For all the datasets taken from the GEO repository, we used the response criteria formulated in the respective original papers first publishing these data. Namely, for two breast cancer datasets, GSE25066 ([@B20]; [@B23]) and GSE41998 ([@B21]), we considered *partial responders* as responders. For the first multiple myeloma dataset, GSE9782 ([@B32]), we took the (non)responder classification used by the authors, where patents with *complete* and *partial response* were annotated as responders, and with *no change* and *progressive disease* -- as non-responders. For three other multiple myeloma datasets, GSE39753 ([@B16]), GSE68871 ([@B41]), and GSE55145 ([@B5]), we considered *complete*, *near-complete* and *very good partial responders* as responders, whereas *partial*, *minor* and *worse* responders -- as non-responders. For the datasets of pediatric Wilms kidney tumor, ALL and AML, extracted from the TARGET gene expression repository of National Cancer Institute ([@B19]), the cases was classified according the distribution of the event-free survival time, which appeared to have two modes with different slopes (Supplementary Figure [S1](#SM5){ref-type="supplementary-material"}).

To preclude any possible bias that may affect the performance of machine-learning classifiers due to unequal representation of samples in two different classes (clinical responders and non-responders), numbers of responding and non-responding cases were equalized within each dataset. Equalization was done by taking the full *smaller* subset of those for the two classes (responders/non-responders), and then by random selection of samples from the *bigger* subset. Thus, each resulting dataset contained equal numbers of cases classified as responders and non-responders.

To engineer a plausible feature space, where the SVM can be applied efficiently, we proposed to select from tens of thousands of individual gene expression features only few of them, which produce a good separation of clinical responders from non-responders. To do so, for every dataset under investigation we selected its particular top 30 genes, whose expression levels taken one by one had the highest ROC AUC values for distinguishing responder and non-responder profiles. We made a number of top informative features equal to 30 because the usual number of samples in considered datasets was not lower than 50 (a direct heuristic number for degree of freedom). These *30 top marker genes*, and response statuses (100 for a responder, 0 for a non-responder) for all selected patients from all datasets are listed on Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

To produce more robust feature selection, for each dataset having, say, *N* samples, the leave-one-out procedure has been performed. Each individual sample was removed from the investigation one at a time, so *N* subdatasets each having *N*-1 individuals were generated. For each subdataset, the ROC AUC test was performed between responders and non-responders for each gene. The genes were next sorted according to their ROC AUC, and top 30 were selected for each subdataset. The final list of such *core informative* genes was generated as an intersection between top 30 selected genes for all *N* subdatasets. For every dataset under investigation, these final core sets are listed in Supplementary Table [S2](#SM2){ref-type="supplementary-material"}; the number of core marker genes is also shown on Table [1](#T1){ref-type="table"}.

Data Trimming for Application in SVM
------------------------------------

We developed a first of its class data trimming^[3](#fn03){ref-type="fn"}^ tool termed FloWPS that has a potential to improve the performance of machine learning methods. Since extrapolation is a widely recognized Achilles heel of SVM ([@B7]; [@B9]; [@B10]; [@B12]), FloWPS avoids it by using the rectangular projections along all irrelevant expression features that cause extrapolation during the SVM-based predictions for every validation point.

In this section we describe and investigate our data trimming procedure (FloWPS) as a preprocessing for SVM application.

Since the number of samples in most of the datasets used here was relatively low, we tested our classifier using the leave-one-out cross-validation method, which introduces lesser errors than the standard five-bin cross-validation scheme generally applied for bigger datasets. According to the leave-one-out approach, for each sample *i =* 1, *N* serves as a validation case whose response to the treatment had to be predicted, whereas all remaining samples, *j* = 1,...(*i*-1),(*i+*1)*,...,N*, collectively acts as a training dataset, and this procedure is repeated for all the samples. For machine leaning without data trimming, in a predefined feature space **F** = (*f*~1~,..., *f~s~* ) every sample *i*, given for the test, is assigned by a classifier, constructed to (*N*-1) samples used for training.

According to the current data trimming approach, instead a fixed space **F** for all *N* testing samples, we propose using an individual space **F***~i~*, which contains individually adapted training data (of *N*-1 samples) for the testing sample *i*. It can be implemented using the following heuristics (Figure [1](#F1){ref-type="fig"}).

![Data trimming pipeline. **(A)** selection of relevant features in FloWPS according to the *m*-condition. A violet dot shows the position of a validation point. Turquoise dots stand for the points from the training dataset. The features (here: *f~1~* and *f~2~*) are considered relevant when they satisfy the criterion that at least *m* flanking training points must be present on both sides relative to the validation point along the feature-specific axis. In the figure, it is exemplified that *m*-condition is satisfied for *f*~1~ feature when *m* = 0 only, and for the *f*~2~, when *m* ≤ 5. **(B)** After selection of the relevant features, only *k* nearest neighbors in the training sets are selected to construct the SVM model. On the figure, *k* = 4, although *k* starting from 20 was used in our calculations, to build SVM model.](fgene-09-00717-g001){#F1}

\(1\) From the whole predefined feature space **F** = (*f*~1~,..., *f*~s~ ) we extract a subset **F***~i~* (*m*), where *m* is a parameter. A feature *f~j~* is kept in **F***~i~*(*m*) if on its axis there are at least *m* projections from training samples, which are larger than *f~j~* (*i*), and, at the same time, at least *m*, which are smaller than *f~j~* (*i*). The procedure for extraction of a subset **F***~i~*(*m*) is illustrated in Figure [1A](#F1){ref-type="fig"} for a two-dimensional space **F** = (*f*~1~, *f*~2~). A violet point stands for the validation sample in the feature space. Turquoise dots represent scattering of the training points. For example, the *m*-condition for the feature *f*~2~ is satisfied when *m* = 0,1,2,3,4,5 (projection of the training set on *f*~2~ axis has five points both below and above the validation point), whereas for the feature *f*~1~ it is satisfied only for *m* = 0 (projection of the validation point on axis *f*~1~ lies outside of the cloud of training points).

\(2\) In **F***~i~* (*m*) we keep for training only *k* closest samples (from given (*N*-1) samples); *k* is also a parameter (Figure [1B](#F1){ref-type="fig"}; note that although for the sake of simplicity *k* = 4 in the picture, in the computational trials we varied *k* from 20 to *N*-1).

Hence, for every individual *i =* 1, *N*, and *m* and *k* parameter values, the predicted classification values are obtained \[i.e., *predictions* *P~i~* (*m*,*k*)*, i =* 1, *N*\]. Considering known response status for each sample *i*, it is possible to calculate AUC values for a whole set of samples as a function over whole range of the parameters *m* and *k* (Figure [2B](#F2){ref-type="fig"}). Since the predicted classification efficiencies depend upon the chosen values for *m* and *k*, it is possible to interrogate the AUC values over the full lattice of all possible (*m*, *k*) pairs.

![Optimization of data trimming parameters *m* and *k* for a given individual. **(A)** Overall scheme for prediction for an individual sample *i* = 1, *N*. All but one individuals serve as a training dataset. For a training dataset at the fitting step, the AUC for a classifier prediction is calculated and plotted **(B)** as a function of data trimming parameters *m* and *k*. Positions of this AUC topogram where AUC \> *p* ⋅ max(AUC), *p* = 0.95, are considered *prediction-accountable* (highlighted with bright yellow color) and form the prediction-accountable set *S*. This AUC topogram, as well as the set *S*, is individual for every validation point *i*.](fgene-09-00717-g002){#F2}

We propose an algorithm of achieving the optimal (*m*,*k*)-settings for a final classifier (Figure [2A](#F2){ref-type="fig"}). The AUC threshold (θ) is set to θ*= p* ⋅ max(AUC), where max(AUC) is the maximal value of AUC, taken over the set of all possible (*m*, *k*) pairs, and the parameter *p* equals to a user-defined confidence threshold. To illustrate performance of this approach, we took two alternative values of *p* = 0.95 or 0.90, and then considered all the (*m*,*k*) pair positions on the AUC(*m*,*k*) topogram. We next screened for the positions where AUC exceeded the threshold θ, and the total combination of these positions was taken as the *prediction-accountable set S* (Figure [2B](#F2){ref-type="fig"}; prediction-accountable positions are shown in yellow). The final prediction of FloWPS (*P~F~*) for a certain validation case should be calculated by averaging the SVM predictions, *P*(*m,k*), over the whole set of positions belonging to the prediction-accountable set *S*, according to the formula: *P~F~* = *mean~S~*(*P*(*m,k*)).

The usual SVM method, i.e., without FloWPS data trimming, corresponds to a very right and bottom corner of the AUC(*m*,*k*) topogram (Figure [2B](#F2){ref-type="fig"}), with the parameter settings *m* = 0, *k* = *N* - 1. On the example shown in Figure [2B](#F2){ref-type="fig"}, the classical SVM, without any doubt, provides essentially lower accuracy than FloWPS.

FloWPS Performance for Default SVM Settings
-------------------------------------------

At first, we investigated performance of FloWPS on ten cancer gene expression datasets (Table [1](#T1){ref-type="table"}) with the default SVM settings (linear kernel and cost/penalty parameter *C* = 1). During our calculations, the FloWPS classifier was first fitted for the training dataset without a sample (say, *i*) to be classified. For these all (*N*-1) samples AUC*~i~*(*m*,*k*) was calculated as a function of data trimming parameters *m* and *k* (see Figure [2A](#F2){ref-type="fig"}). This enabled finding the prediction-accountable set *S~i~* in the AUC*~i~*(*m*,*k*) topogram (on Figure [2B](#F2){ref-type="fig"}, the set was marked with bright yellow). The *m* and *k* values from the set *S~i~* were then used for data trimming and classifying of a single sample *i*. In parallel, we applied the standard SVM algorithm for leave-one-out cross-validation without data trimming, i.e., *m* = 0, *k* = *N*-1 for each training sub-dataset. The comparison is shown on Table [2](#T2){ref-type="table"}, Supplementary Table [S3](#SM3){ref-type="supplementary-material"}, and Figures [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}.

###### 

Performance of clinical response classifiers for clinically annotated gene expression datasets.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dataset                                                 Top 30 marker genes   Core marker genes                                                                                      
  ------------------------------------------------------- --------------------- ------------------- ---------- ------ ---------- ------ ---------- ------ ---------- ------ ---------- ------
  GSE25066 ([@B20];\                                      **0.70**              0.28                **0.76**   0.10   **0.77**   0.13   **0.73**   0.26   **0.76**   0.25   **0.76**   0.23
  [@B23])                                                                                                                                                                              

  GSE41998 ([@B21])                                       **0.79**              0.25                **0.87**   0.14   **0.91**   0.14   **0.87**   0.14   **0.89**   0.15   **0.92**   0.12

  GSE9782 ([@B32])                                        **0.73**              0.28                **0.78**   0.22   **0.76**   0.17   **0.68**   0.33   **0.71**   0.33   **0.72**   0.34

  GSE39754 ([@B16])                                       **0.65**              0.36                **0.68**   0.27   **0.71**   0.34   **0.65**   0.36   **0.68**   0.36   **0.72**   0.35

  GSE68871 ([@B41])                                       **0.66**              0.35                **0.75**   0.25   **0.74**   0.27   **0.68**   0.33   **0.78**   0.20   **0.77**   0.24

  GSE55145 ([@B5])                                        **0.84**              0.19                **0.86**   0.11   **0.90**   0.11   **0.77**   0.24   **0.81**   0.19   **0.82**   0.06

  TARGET-50 ([@B19]; [@B45])                              **0.64**              0.35                **0.75**   0.13   **0.78**   0.16   **0.72**   0.26   **0.81**   0.08   **0.82**   0.09

  TARGET-10 ([@B19]; [@B42])                              **0.85**              0.16                **0.86**   0.14   **0.87**   0.12   **0.87**   0.13   **0.94**   0.07   **0.94**   0.04

  TARGET-20 ([@B19]) with busulfan and cyclophosphamide   **0.74**              0.26                **0.79**   0.16   **0.79**   0.17   **0.76**   0.23   **0.77**   0.22   **0.83**   0.00

  TARGET-20 ([@B19]) w/o busulfan and cyclophosphamide    **0.73**              0.28                **0.76**   0.30   **0.76**   0.27   **0.74**   0.26   **0.77**   0.13   **0.79**   0.11

                                                                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Area-under-curve (AUC) and false discovery rate (FDR) values calculated for each version of a classifier are shown. All calculations were made using leave-one-out cross-validation approach.

![Distribution (violin plots together with each instance showed as a red/green dot) of FloWPS predictions (*P~F~*) for patients without (red plots and dots) and with (green plots and dots) positive clinical response to chemotherapy treatment. For FloWPS, *core marker genes* and *p* = 0.90 settings were used. Black horizontal line shows the discrimination threshold (τ) between responders and non-responders for each classifier. Panels represent different data sources, **(A)** GSE25066; **(B)** GSE41998; **(C)** GSE9782; **(D)** GSE39754; **(E)** GSE68871; **(F)** GSE55134; **(G)** TARGET-50; **(H)** TARGET-10; **(I)** and **(J)**: TARGET-20 with and without busulfan and cyclophosphamide, respectively.](fgene-09-00717-g003){#F3}

![Receiver--operator curves (ROC) showing the dependence of sensitivity (*Sn*) upon specificity (*Sp*) for FloWPS-based classifier of treatment response for datasets with *core marker genes*. Red dots: confidence parameter *p* = 0.95, blue dots: *p* = 0.90. Panels represent different clinically annotated datasets, **(A)** GSE25066; **(B)** GSE41998; **(C)** GSE9782; **(D)** GSE39754; **(E)** GSE68871; **(F)** GSE55134; **(G)** TARGET-50; **(H)** TARGET-10; **(I,J)** TARGET-20 with and without busulfan and cyclophosphamide, respectively.](fgene-09-00717-g004){#F4}

The discrimination threshold (τ), which is shown as a black horizontal line on Figure [3](#F3){ref-type="fig"} (so that any sample with FloWPS prediction value above τ is classified as a responder, and below it -- as a non-responder), was set to minimize the sum of FP and FN predictions.

For every dataset, confidence parameter *p* and scheme of gene selection, FloWPS classifier demonstrated the ROC AUC exceeding the corresponding value for the classical SVM (Table [2](#T2){ref-type="table"}). For three datasets out of ten, AUC for classical SVM was between 0.64 and 0.68. For all these cases, application of FloWPS with confidence level *p* = 0.90 enabled obtaining essentially better AUC values ranging between 0.71 and 0.78.

The comparison of classifier's quality by another metric, the FDR^[4](#fn04){ref-type="fn"}^, has demonstrated similar results: FDR was lower for FloWPS than for classical SVM for almost all the cases (Table [2](#T2){ref-type="table"}, columns without boldface font). Other metrics, such as sensitivity (Sn), specificity (Sp), accuracy rate (ACC) and MCC^[5](#fn05){ref-type="fn"}^ also strongly tend to be higher for FloWPS than for classical SVM without data trimming (Supplementary Table [S3](#SM3){ref-type="supplementary-material"}).

FloWPS Performance at Different Settings and Comparison With Alternative Data Reduction Approach
------------------------------------------------------------------------------------------------

Although the classifier quality tended to be higher for data trimming than for default SVM settings, the advantages were different in different cancer datasets. The FloWPS performance, therefore, was investigated for different SVM kernels (linear vs. polynomial) and different values for cost/penalty parameters *C* (ranged from 0.1 to 1000), Figure [5](#F5){ref-type="fig"} and Supplementary Table [S4](#SM4){ref-type="supplementary-material"}. These calculations were done for the core marker gene datasets and FloWPS confidence parameter *p* = 0.90. The advantage of FloWPS over SVM is more essential in the conditions vulnerable to SVM overtraining, e.g., for linear kernel with high values of the cost/penalty parameter (C = 100 or 1000) or for polynomial kernel, where SVM may be easily overfitted. Fortunately, FloWPS precludes such overfitting, thus raising AUC and decreasing FDR. The same pattern was also seen for the Sn, Sp, ACC and MCC values (Supplementary Table [S4](#SM4){ref-type="supplementary-material"}).

![AUC and FDR for (non)responders classifier as a function of cost/penalty parameter *C* for classical SVM (without data trimming) and FloWPS for both linear and polynomial kernels. Calculations were done for core marker gene datasets and confidence parameter *p* = 0.90. Different panels represent different datasets, **(A)** GSE25066; **(B)** GSE41998; **(C)** GSE9782; **(D)** GSE39754; **(E)** GSE68871; **(F)** GSE55134; **(G)** TARGET-50; **(H)** TARGET-10; **(I,J)** TARGET-20 with and without busulfan and cyclophosphamide, respectively. **(K)** Legend showing FloWPS and SVM modifications.](fgene-09-00717-g005){#F5}

Note that FloWPS is not the only possible data reduction/feature selection method, which may be used for preprocessing to improve the classifier's quality. To try a simple alternative to FloWPS, which is, however, not specific to individual samples, we did calculations based on PCA mode rather than original features. The number of PCs taken for building the SVM model, may act as a parameter, which is optimized in a manner similar to optimization of *m* and *k* for FloWPS. Namely, a maximum for AUC as a function of PC number is found and then used as the optimal number of PCs for an SVM-based prediction.

Thus, we compared the classifier qualities for three methods, namely classical SVM without data reduction, PCA-assisted SVM with pre-trained PC number, and FloWPS with the confidence parameter *p* = 0.90 (Table [3](#T3){ref-type="table"}; note that both classical SVM and FloWPS calculations were done using gene expression features rather than PCs). The calculations were done for core marker gene datasets and cost/penalty SVM parameters *C* = 1 and 100. For linear kernel, several datasets had comparable AUC for simple PCA-assisted data reduction and for FloWPS (Table [3](#T3){ref-type="table"}). However, for polynomial kernel FloWPS essentially outperformed the PCA-assisted data reduction, most likely due to bigger risk of overtraining for SVM with nonlinear kernels.

###### 

AUC of (non)responder classifier for classical SVM without data reduction (SVM), PCA-assisted SVM (PCA) and FloWPS with confidence parameter *p* = 0.90.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dataset                                                 Linear kernel   Polynomial kernel                                                                  
  ------------------------------------------------------- --------------- ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  GSE25066 ([@B20];\                                      0.73            0.77                0.76   0.63   0.77   0.75   0.65   0.67   0.74   0.63   0.66   0.75
  [@B23])                                                                                                                                                    

  GSE41998 ([@B21])                                       0.87            0.84                0.92   0.82   0.88   0.86   0.60   0.62   0.69   0.75   0.74   0.81

  GSE9782 ([@B32])                                        0.68            0.72                0.72   0.60   0.72   0.72   0.62   0.68   0.73   0.64   0.68   0.76

  GSE39754 ([@B16])                                       0.69            0.68                0.72   0.56   0.68   0.71   0.66   0.61   0.67   0.65   0.61   0.68

  GSE68871 ([@B41])                                       0.68            0.68                0.77   0.69   0.68   0.76   0.64   0.65   0.72   0.69   0.76   0.74

  GSE55145 ([@B5])                                        0.77            0.84                0.82   0.77   0.84   0.85   0.63   0.73   0.77   0.80   0.73   0.83

  TARGET-50 ([@B19]; [@B45])                              0.72            0.75                0.82   0.68   0.76   0.81   0.68   0.64   0.73   0.65   0.72   0.74

  TARGET-10 ([@B19]; [@B42])                              0.87            0.85                0.94   0.82   0.83   0.94   0.68   0.65   0.85   0.78   0.83   0.86

  TARGET-20 ([@B19]) with busulfan and cyclophosphamide   0.76            0.78                0.83   0.70   0.80   0.82   0.63   0.63   0.77   0.83   0.72   0.82

  TARGET-20 ([@B19]) w/o busulfan and cyclophosphamide    0.74            0.81                0.79   0.65   0.79   0.79   0.69   0.68   0.77   0.72   0.69   0.79

                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

It was seen previously that SVM sometimes fails when it is intended for distinguishing fine biomedical properties such as disease progression prognosis or assessment of clinical efficiency of drugs for an individual patient, using high throughput molecular data, e.g., complete DNA mutation or gene expression profiles ([@B34]; [@B8]). Particularly, for many biologically relevant applications, SVM occurred either fully incapable to predict drug sensitivity ([@B43]), or demonstrated poorer performance than competing method for machine learning ([@B18]; [@B17]; [@B24]; [@B28]; [@B35]; [@B47]). Thus, the tool for improvement of SVM performance is certainly needed.

In this study, we investigated ten sets of gene expression data for cancer patients treated with different anti-cancer drugs with known clinical outcomes, where the original dimension of samples (patients) is many hundreds times larger than the numbers of patients. So, the first problem in such applications was to extract an appropriate number of features, in which space one could achieve a classifier-predictor with a high level of quality. There are many authors focused to resolve the preprocessing problem ([@B38]; [@B26]; [@B39]; [@B29]; [@B40]). Some feature selection methods, like the DWFS wrapping tool ([@B37]), use sophisticatedly designed approaches such as genetic algorithms to improve the classifier quality. In this paper we proposed one more, FloWPS, which is very different from all known. Its critical characteristic is that for every single new sample, which class has to be predicted, the method extracted its individual sub-space and, more, in that subspace takes for training data an appropriate subset of samples.

FloWPS data trimming method simultaneously combines the advantages of both *global* (like SVM) and local (like kNN) ([@B4]) methods of machine learning, and successfully acts even when purely local and global approaches fail. The failure of SVM, which we have observed at least for 3 out of 10 datasets in the current study (Table [2](#T2){ref-type="table"}), means that there is no strict *distant order* in the placement of responder and non-responder points in the space of gene expression features. Yet, the lack of *distant* order does not necessary mean the absence of *local* order (Figure [6](#F6){ref-type="fig"}). The latter may be detected using *local* methods such as kNN, which has been confirmed by our FloWPS (Table [2](#T2){ref-type="table"} and Figures [3](#F3){ref-type="fig"}, [5](#F5){ref-type="fig"}). The FloWPS advantages are better seen for SVM with polynomial than for linear kernel due to higher risk of overtraining on such models (Figure [5](#F5){ref-type="fig"} and Table [3](#T3){ref-type="table"}).

![**(A)** Global machine learning methods, such as SVM, may fail to separate classes in datasets without global order. **(B)** Machine-learning with data trimming works locally and may separate classes more accurately.](fgene-09-00717-g006){#F6}

We hypothesize that FloWPS and data trimming may be also helpful for improving other learning methods based on multi-omics data, including nowadays-flourishing deep learning approaches ([@B11]; [@B27]; [@B36]).

Materials and Methods {#s1}
=====================

Preprocessing of Gene Expression Data
-------------------------------------

For the datasets investigated using the Affymetrix microarray hybridization platforms, gene expression data were taken from the series matrices deposited in the GEO public repository and then quantile-normalized ([@B14]) using the R package *preprocessCore* ([@B13]). All pediatric datasets taken from the TARGET database ([@B19]) contained results of NGS mRNA profiling at Illumina HiSeq 2000 platforms; they were normalized using R package *DESeq2* ([@B30]).

SVM Calculations
----------------

All the SVM calculations with linear and polynomial kernels were performed using the Python package *sklearn* ([@B33]) that employs the C++ library 'libsvm' ([@B15]). The penalty parameter *C* varied from 0.1 to 1000 for different calculations. Other SVM parameters had the default settings for the *sklearn* package.

Plot Preparations
-----------------

AUC(*m*,*k*) topograms, like Figure [2B](#F2){ref-type="fig"}, were plotted using *mathplotlib* Python library ([@B22]). Violin plots for FloWPS predictions (see Figure [3](#F3){ref-type="fig"}) for responders and non-responders were plotted using the *ggplot2* R package ([@B46]).

Availability of Data and Materials
==================================

The datasets analyzed during the current study are available in the GEO repository,

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25066>

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41998>

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9782>

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39754>

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68871>

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55145>

<ftp://caftpd.nci.nih.gov/pub/OCG-DCC/TARGET/WT/mRNA-seq/>

<ftp://caftpd.nci.nih.gov/pub/OCG-DCC/TARGET/AML/mRNA-seq/>

<ftp://caftpd.nci.nih.gov/pub/OCG-DCC/TARGET/ALL/mRNA-seq/>

The Python module that performs data trimming according to the FloWPS method for different values of parameters *m* and *k*, as well as the R code that makes FloWPS predictions using the results obtained with the Python module, and a README manual how to use these codes, were deposited on Gitlab and are available by the link: <https://gitlab.com/oncobox/flowps>.
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This is the result of a PubMed query <https://www.ncbi.nlm.nih.gov/pubmed/?term=support+vector+machine_>

The ROC (receiver--operator curve) is a widely-used graphical plot that illustrates the diagnostic ability of a binary classifier system as its discrimination threshold is varied. The ROC is created by plotting the true positive rate (TPR) against the false positive rate (FPR) at various threshold settings. The area under the ROC curve, called ROC AUC, or simply AUC, is routinely employed for assessment of any classifier's quality.

Data trimming is the process of removing or excluding extreme values, or outliers, from a dataset ([@B44]).

FDR shows the percentage of *false positive* (FP) predictions among all those classified as positive, FDR = FP/(FP + TP), where TP means *true positive*.

MCC can be calculated from the confusion matrix, $MCC = \frac{TP \cdot TN - FP \cdot FN}{\sqrt{\left( {TP + FP} \right)\left( {TP + FN} \right)\left( {TN + FP} \right)\left( {TN + FN} \right)}}$
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ALL

:   acute lymphoblastic leukemia

AML

:   acute myelogenous leukemia

ASCT

:   allogeneic stem cell transplantation

AUC

:   area under curve

FDR

:   false discovery rate

FloWPS

:   floating window projective separator

FP

:   false positive

FN

:   false negative

GEO

:   gene expression omnibus

GSE

:   GEO series

HER2

:   human epidermal growth factor receptor 2

kNN

:   *k* nearest neighbors

MCC

:   Matthews correlation coefficient

mRNA

:   messenger ribonucleic acid

NGS

:   next-generation sequencing

PC

:   principal component

PCA

:   principal component analysis

ROC

:   receiver operating characteristic

SVM

:   support vector machine

TN

:   true negative

TP

:   true positive

VTD

:   velcade, thalidomide and dexamethasone

[^1]: Edited by: Tao Huang, Shanghai Institutes for Biological Sciences (CAS), China

[^2]: Reviewed by: Guilherme De Alencar Barreto, Universidade Federal do Ceará, Brazil; Firoz Ahmed, Jeddah University, Saudi Arabia

[^3]: This article was submitted to Bioinformatics and Computational Biology, a section of the journal Frontiers in Genetics
